[Efectiveness and safety of switching to raltegravir-based regimen in dyslipidemic HIV-infected patients receiving antiretroviral therapy at Arriaran Foundation].
Efectividad y seguridad del cambio a esquema basado en raltegravir en pacientes con infección por VIH dislipidémicos bajo terapia anti-retroviral en Fundación Arriarán.
Adult
Anti-HIV Agents
/ administration & dosage
Antiretroviral Therapy, Highly Active
/ methods
CD4 Lymphocyte Count
Cohort Studies
Dyslipidemias
/ prevention & control
Female
Follow-Up Studies
HIV Infections
/ blood
HIV Protease Inhibitors
/ adverse effects
Humans
Male
Middle Aged
Raltegravir Potassium
/ administration & dosage
Retrospective Studies
Viral Load
Journal
Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia
ISSN: 0717-6341
Titre abrégé: Rev Chilena Infectol
Pays: Chile
ID NLM: 9305754
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
12
08
2018
accepted:
28
03
2019
entrez:
21
12
2019
pubmed:
21
12
2019
medline:
25
2
2020
Statut:
ppublish
Résumé
The impact of switching antiretroviral therapy (ART) regimen for dyslipidemia management in HIV-infected (HIV+) patients has not been reported in Chile. To assess effectiveness and safety at 12 months after switching to raltegravir-based regimen for dyslipidemia management. Retrospective cohort of HIV+ patients receiving ART at Arriaran Foundation, with dyslipidemia switched to raltegravir-based regimen for lipid management. 73 patients were included, receiving ART based in nonnucleoside reverse transcriptase inhibitor (NNRTI; 50,7%) or protease inhibitor (PI; 49,3%), with mixed dyslipidemia (42,5%) or isolated hypertriglyceridemia (57,5%). At baseline, median total cholesterol (TC) and triglycerides (TG) were 228 mg/dl and 420 mg/dl, respectively; undetectable viral load (VL) was present in 94,5% of patients. Backbone ART was switched in 58,4% and lipid-lowering therapy was used by 89,1% of them. At 12 months, there was a significant decrease in TG (-43,6%) and TC (-19,3%). No cases of virologic failure were observed, although 10,9% of patients had detectable VL at 12 months, mostly transient. Switching ART to raltegravir-based regimen in dyslipidemic patients receiving NNRTI or PI is associated with a significative decrease in TG and TC at 12 months. This strategy is safe, but VL can be increased temporarily.
Sections du résumé
BACKGROUND
BACKGROUND
The impact of switching antiretroviral therapy (ART) regimen for dyslipidemia management in HIV-infected (HIV+) patients has not been reported in Chile.
AIM
OBJECTIVE
To assess effectiveness and safety at 12 months after switching to raltegravir-based regimen for dyslipidemia management.
METHODS
METHODS
Retrospective cohort of HIV+ patients receiving ART at Arriaran Foundation, with dyslipidemia switched to raltegravir-based regimen for lipid management.
RESULTS
RESULTS
73 patients were included, receiving ART based in nonnucleoside reverse transcriptase inhibitor (NNRTI; 50,7%) or protease inhibitor (PI; 49,3%), with mixed dyslipidemia (42,5%) or isolated hypertriglyceridemia (57,5%). At baseline, median total cholesterol (TC) and triglycerides (TG) were 228 mg/dl and 420 mg/dl, respectively; undetectable viral load (VL) was present in 94,5% of patients. Backbone ART was switched in 58,4% and lipid-lowering therapy was used by 89,1% of them. At 12 months, there was a significant decrease in TG (-43,6%) and TC (-19,3%). No cases of virologic failure were observed, although 10,9% of patients had detectable VL at 12 months, mostly transient.
CONCLUSIONS
CONCLUSIONS
Switching ART to raltegravir-based regimen in dyslipidemic patients receiving NNRTI or PI is associated with a significative decrease in TG and TC at 12 months. This strategy is safe, but VL can be increased temporarily.
Identifiants
pubmed: 31859773
pii: S0716-10182019000400490
doi: 10.4067/S0716-10182019000400490
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
HIV Protease Inhibitors
0
Raltegravir Potassium
43Y000U234
Types de publication
Journal Article
Langues
spa
Sous-ensembles de citation
IM